In a patient with left ventricular ejection fraction less than 40% presenting with rapid atrial fibrillation (ventricular rate >110 beats per minute) who is already taking nebivolol, what is the first‑line intravenous therapy for acute rate control?

Intravenous digoxin or amiodarone is the first-line therapy for acute rate control in this patient.

Given that this patient has LVEF <40% and is already taking nebivolol (a beta-blocker), adding additional intravenous beta-blockers or calcium channel blockers is contraindicated or requires extreme caution due to the risk of worsening heart failure and hemodynamic compromise.

Rationale Based on Guidelines

The 2014 AHA/ACC/HRS guidelines provide clear Class I recommendations for patients with heart failure and reduced ejection fraction presenting with rapid atrial fibrillation 1, 2:

• In the absence of pre-excitation, intravenous digoxin or amiodarone is recommended to control heart rate acutely in patients with HF (Level of Evidence: B)
• Intravenous beta-blocker administration is recommended to slow ventricular response in the acute setting, but with caution needed in patients with overt congestion, hypotension, or HF with reduced LVEF 1, 2

The 2024 ESC guidelines reinforce this approach 3:

• Beta-blockers and/or digoxin are recommended in patients with AF and LVEF ≤40% to control heart rate (Class I, Level B)
• Intravenous amiodarone, digoxin, esmolol, or landiolol may be considered in patients with hemodynamic instability or severely depressed LVEF to achieve acute control (Class IIb, Level B)

Why Not Additional Beta-Blocker?

Since the patient is already on nebivolol, adding intravenous beta-blockers carries significant risks:

1. Risk of excessive bradycardia and heart block when combining beta-blockers 4, 2
2. Potential for hemodynamic decompensation in the setting of reduced LVEF 1, 2
3. The 2014 guidelines explicitly state that intravenous nondihydropyridine calcium channel antagonists and beta blockers should not be administered to patients with decompensated HF (Class III: Harm) 1

Why Not Calcium Channel Blockers?

Nondihydropyridine calcium channel blockers (diltiazem, verapamil) are contraindicated in this scenario:

• The guidelines state these agents "should be used cautiously or avoided in patients with HF due to systolic dysfunction" 5
• Class III recommendation: In patients with decompensated HF and AF, intravenous administration of a nondihydropyridine calcium channel antagonist may exacerbate hemodynamic compromise 6, 7

Digoxin vs. Amiodarone: Which to Choose First?

Start with intravenous digoxin as the initial agent:

• Digoxin is specifically effective for rate control in patients with HF and reduced EF 2
• It has a Class I recommendation for this exact clinical scenario 1, 2
• Digoxin is particularly useful when there is hypotension or heart failure 4
• The 2008 ESC guidelines note that digoxin is useful for initial control of ventricular rate in patients with rapid AF and may be considered in decompensated HF patients 8

Reserve intravenous amiodarone for:

• When digoxin alone fails to achieve adequate rate control
• When other measures are unsuccessful or contraindicated (Class IIa recommendation) 1, 2
• The 2014 AATS guidelines state: "For patients with hypotension, heart failure or LV dysfunction, or when other measures are unsuccessful or contraindicated, intravenous amiodarone can be useful" 4

Practical Implementation

Digoxin dosing:

• Loading dose: 0.25 mg IV every 2 hours, up to 1.5 mg total 6
• Onset: 60 minutes or more, with peak effect at 6 hours 5
• Maintenance: 0.125 to 0.375 mg daily IV or orally 6

If digoxin is insufficient, add amiodarone:

• Loading: 150 mg IV over 10 minutes 6
• Maintenance: 0.5 to 1 mg/min IV 6
• Note: Amiodarone requires several hours for efficacy 5

Critical Caveats

1. Monitor for bradycardia when combining rate-control agents, especially since the patient is already on nebivolol 4, 2
2. Check electrolytes and renal function before and during digoxin therapy, as hypokalaemia increases risk of digoxin toxicity 8
3. Consider anticoagulation if AF persists >48 hours 4
4. Avoid AV nodal blockers if there is any suspicion of pre-excitation (WPW syndrome) 4, 1, 6
5. Combination therapy (digoxin + beta-blocker already on board) is reasonable and often necessary, but requires careful dose titration to avoid excessive bradycardia 2, 5

The evidence consistently supports that in patients with LVEF <40% already on beta-blocker therapy presenting with rapid AF, intravenous digoxin is the safest and most appropriate first-line agent, with amiodarone reserved as second-line therapy.